Intercoastal Medical Group

Sarasota, Florida 34239-3228

7 studies enrolling now · 34 studies all time

What they study most

Acute Ischemic Stroke, Acute Myocardial Infarction (AMI), Alzheimer Disease, Alzheimer's Disease, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Risk, Constipation, Coronary Heart Disease (CHD), Early Alzheimer's Disease, Early Alzheimer´s Disease, Epilepsy

Studies at this site

• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) — Recruiting now
• ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
• Lead Evaluation for Defibrillation and Reliability Post Approval Study — Enrolling by invitation
• A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease — Completed
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• Enlighten Study: The EV-ICD Post Approval Registry — Running, not enrolling
• A Study of Seltorexant in Participants With Probable Alzheimer's Disease — Completed
• Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) — Completed
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover) — Stopped early
• Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) — Completed
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism — Completed
• PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window — Completed
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy — Completed
• Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization — Stopped early
• The Intravascular Cooling in the Treatment of Stroke 2/3 Trial — Stopped early